Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis.

Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ.

Neuroophthalmology. 2019 May 28;44(1):1-4. doi: 10.1080/01658107.2019.1607883. eCollection 2020 Feb.

PMID:
32076441
2.

The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.

Höftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, Joldic D, Pittock SJ, Tillema JM, Gorman M, Lassmann H, Lucchinetti CF.

Acta Neuropathol. 2020 Feb 11. doi: 10.1007/s00401-020-02132-y. [Epub ahead of print]

PMID:
32048003
3.

International multicenter examination of MOG antibody assays.

Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, Fryer JP, Mills J, Teegen B, Mindorf S, Ritter N, Krummrei U, Stöcker W, Eggert J, Flanagan EP, Ramberger M, Hegen H, Rostasy K, Berger T, Leite MI, Palace J, Irani SR, Dale RC, Probst C, Probst M, Brilot F, Pittock SJ, Waters P.

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2). pii: e674. doi: 10.1212/NXI.0000000000000674. Print 2020 Mar 5.

4.

Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?

Kunchok A, Krecke KN, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga AS, Chen JJ, Weinshenker BG, Pittock SJ.

Neurology. 2020 Jan 14;94(2):85-88. doi: 10.1212/WNL.0000000000008786. Epub 2019 Dec 11. No abstract available.

PMID:
31827002
5.

Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG.

Jitprapaikulsan J, Klein CJ, Pittock SJ, Gadoth A, McKeon A, Mills JR, Dubey D.

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):328-330. doi: 10.1136/jnnp-2019-322175. Epub 2019 Dec 4. No abstract available.

6.

Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.

Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, Devine M, Cerhan JH, Dunlay K, Sagen J, Ramberger M, Waters P, Irani SR, Pittock SJ.

Ann Neurol. 2020 Feb;87(2):313-323. doi: 10.1002/ana.25655. Epub 2019 Dec 14.

7.

IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS.

Shelly S, Mills JR, Martinez-Thompson JM, Rofforth MM, Pittock SJ, Mandrekar J, Triplett JD, Mauermann M, Dubey D, Klein CJ.

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):324-326. doi: 10.1136/jnnp-2019-321977. Epub 2019 Nov 22. No abstract available.

PMID:
31757814
8.

The frequency of longitudinally extensive transverse myelitis in MS: A population-based study.

Asnafi S, Morris PP, Sechi E, Pittock SJ, Weinshenker BG, Palace J, Messina S, Flanagan EP.

Mult Scler Relat Disord. 2019 Oct 31;37:101487. doi: 10.1016/j.msard.2019.101487. [Epub ahead of print]

PMID:
31707235
9.

Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema.

Cohen DA, Bhatti MT, Pulido JS, Lennon VA, Dubey D, Flanagan EP, Pittock SJ, Klein CJ, Chen JJ.

Ophthalmology. 2020 Feb;127(2):221-229. doi: 10.1016/j.ophtha.2019.09.012. Epub 2019 Sep 20.

PMID:
31676123
10.

Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients.

Kunchok A, Chen JJ, McKeon A, Mills JR, Flanagan EP, Pittock SJ.

JAMA Neurol. 2019 Oct 28. doi: 10.1001/jamaneurol.2019.3656. [Epub ahead of print] No abstract available.

PMID:
31657826
11.

Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome.

Dubey D, Jitprapaikulsan J, Bi H, Do Campo RV, McKeon A, Pittock SJ, Engelstad JK, Mills JR, Klein CJ.

Neurology. 2019 Nov 12;93(20):e1873-e1880. doi: 10.1212/WNL.0000000000008472. Epub 2019 Oct 17.

PMID:
31624089
12.

Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica.

Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, Helenowski I, Jitprapaikulsan J, Fryer JP, Pittock SJ.

Neurology. 2019 Oct 29;93(18):e1732-e1741. doi: 10.1212/WNL.0000000000008394. Epub 2019 Oct 2.

PMID:
31578302
13.

Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg.

Turner LE, Pittock SJ, McEvoy MT, Flanagan EP.

Neurol Neuroimmunol Neuroinflamm. 2019 Sep 25;6(6). pii: e620. doi: 10.1212/NXI.0000000000000620. Print 2019 Nov. No abstract available.

14.

Reader response: Unintended consequences of Mayo paraneoplastic evaluations.

Pittock SJ, Mills JR, McKeon A.

Neurology. 2019 Sep 24;93(13):606. doi: 10.1212/WNL.0000000000008179. No abstract available.

PMID:
31551274
15.

Neurochondrin neurological autoimmunity.

Shelly S, Kryzer TJ, Komorowski L, Miske R, Anderson MD, Flanagan EP, Hinson SR, Lennon VA, Pittock SJ, McKeon A.

Neurol Neuroimmunol Neuroinflamm. 2019 Sep 11;6(6). pii: e612. doi: 10.1212/NXI.0000000000000612. Print 2019 Nov.

16.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators.

Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.

PMID:
31495497
17.

Optic neuritis in the era of biomarkers.

Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT.

Surv Ophthalmol. 2020 Jan - Feb;65(1):12-17. doi: 10.1016/j.survophthal.2019.08.001. Epub 2019 Aug 16. Review.

PMID:
31425702
18.

Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka.

Senanayake B, Jitprapaikulsan J, Aravinthan M, Wijesekera JC, Ranawaka UK, Riffsy MT, Paramanathan T, Sagen J, Fryer JP, Schmeling J, Majed M, Flanagan EP, Pittock SJ.

J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1381-1383. doi: 10.1136/jnnp-2018-320243. Epub 2019 Aug 6. No abstract available.

19.

Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.

Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, Komorowski L, Scharf M, Hinson SR, Lennon VA, Pittock SJ, Klein CJ, McKeon A.

Neurology. 2019 Sep 3;93(10):e954-e963. doi: 10.1212/WNL.0000000000008061. Epub 2019 Aug 1. Erratum in: Neurology. 2019 Oct 1;93(14):647.

20.

Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS.

Lopez-Chiriboga S, Pittock SJ, Weinshenker BG, Chen JJ, Flanagan E.

Mult Scler Relat Disord. 2019 Oct;35:34-35. doi: 10.1016/j.msard.2019.06.037. Epub 2019 Jun 29. No abstract available.

PMID:
31299419
21.

Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.

Mandel-Brehm C, Dubey D, Kryzer TJ, O'Donovan BD, Tran B, Vazquez SE, Sample HA, Zorn KC, Khan LM, Bledsoe IO, McKeon A, Pleasure SJ, Lennon VA, DeRisi JL, Wilson MR, Pittock SJ.

N Engl J Med. 2019 Jul 4;381(1):47-54. doi: 10.1056/NEJMoa1816721.

22.

Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.

Sechi E, Shosha E, Williams JP, Pittock SJ, Weinshenker BG, Keegan BM, Zalewski NL, Lopez-Chiriboga AS, Jitprapaikulsan J, Flanagan EP.

Neurology. 2019 Jul 23;93(4):e414-e420. doi: 10.1212/WNL.0000000000007828. Epub 2019 Jun 24.

PMID:
31235660
23.

GABAA receptor autoimmunity: A multicenter experience.

O'Connor K, Waters P, Komorowski L, Zekeridou A, Guo CY, Mgbachi VC, Probst C, Mindorf S, Teegen B, Gelfand JM, Geschwind MD, Lennon V, Pittock SJ, McKeon A.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 4;6(3):e552. doi: 10.1212/NXI.0000000000000552. eCollection 2019 May.

24.

Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up.

Petzold A, Woodhall M, Khaleeli Z, Tobin WO, Pittock SJ, Weinshenker BG, Vincent A, Waters P, Plant GT.

J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1021-1026. doi: 10.1136/jnnp-2019-320493. Epub 2019 May 22.

PMID:
31118222
25.

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM.

N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.

PMID:
31050279
26.

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.

Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D, Takai Y, Leite MI, Weinshenker B, Cabre P, Jacob A, Nakashima I, Fujihara K, Pittock SJ.

Brain. 2019 May 1;142(5):1310-1323. doi: 10.1093/brain/awz054.

27.

Isolated recurrent myelitis in a persistent MOG positive patient.

Anis S, Regev K, Pittock SJ, Flanagan EP, Alcalay Y, Gadoth A.

Mult Scler Relat Disord. 2019 May;30:163-164. doi: 10.1016/j.msard.2019.02.016. Epub 2019 Feb 13.

PMID:
30780123
28.

A mouse model of seizures in anti-N-methyl-d-aspartate receptor encephalitis.

Taraschenko O, Fox HS, Pittock SJ, Zekeridou A, Gafurova M, Eldridge E, Liu J, Dravid SM, Dingledine R.

Epilepsia. 2019 Mar;60(3):452-463. doi: 10.1111/epi.14662. Epub 2019 Feb 11.

PMID:
30740690
29.

A multicenter comparison of MOG-IgG cell-based assays.

Waters PJ, Komorowski L, Woodhall M, Lederer S, Majed M, Fryer J, Mills J, Flanagan EP, Irani SR, Kunchok AC, McKeon A, Pittock SJ.

Neurology. 2019 Mar 12;92(11):e1250-e1255. doi: 10.1212/WNL.0000000000007096. Epub 2019 Feb 6.

30.

Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability.

Dubey D, Pittock SJ, McKeon A.

Epilepsia. 2019 Feb;60(2):367-369. doi: 10.1111/epi.14649. No abstract available.

31.

Optical coherence tomography is highly sensitive in detecting prior optic neuritis.

Xu SC, Kardon RH, Leavitt JA, Flanagan EP, Pittock SJ, Chen JJ.

Neurology. 2019 Feb 5;92(6):e527-e535. doi: 10.1212/WNL.0000000000006873. Epub 2019 Jan 23.

PMID:
30674600
32.

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP.

JAMA Neurol. 2019 Mar 1;76(3):301-309. doi: 10.1001/jamaneurol.2018.4053.

33.

Age is a critical determinant in recovery from multiple sclerosis relapses.

Conway BL, Zeydan B, Uygunoğlu U, Novotna M, Siva A, Pittock SJ, Atkinson EJ, Rodriguez M, Kantarci OH.

Mult Scler. 2019 Nov;25(13):1754-1763. doi: 10.1177/1352458518800815. Epub 2018 Oct 10.

PMID:
30303037
34.

Paraneoplastic neuronal intermediate filament autoimmunity.

Basal E, Zalewski N, Kryzer TJ, Hinson SR, Guo Y, Dubey D, Benarroch EE, Lucchinetti CF, Pittock SJ, Lennon VA, McKeon A.

Neurology. 2018 Oct 30;91(18):e1677-e1689. doi: 10.1212/WNL.0000000000006435. Epub 2018 Oct 3.

35.

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD.

Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ.

Neurology. 2018 Oct 23;91(17):e1642-e1651. doi: 10.1212/WNL.0000000000006392. Epub 2018 Sep 26.

36.

Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies.

Xu M, Bennett DLH, Querol LA, Wu LJ, Irani SR, Watson JC, Pittock SJ, Klein CJ.

J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):177-188. doi: 10.1136/jnnp-2018-318556. Epub 2018 Sep 17. Review.

PMID:
30224548
37.

Population-based study of "no evident disease activity" in MS.

Parks NE, Pittock SJ, Mandrekar J, Kantarci OH, Lucchinetti CF, Weinshenker BG, Keegan BM, Tobin WO, Tillema JM, Toledano M, Flanagan EP.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 16;5(6):e495. doi: 10.1212/NXI.0000000000000495. eCollection 2018 Nov.

38.

Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction.

Dubey D, Kothapalli N, McKeon A, Flanagan EP, Lennon VA, Klein CJ, Britton JW, So E, Boeve BF, Tillema JM, Sadjadi R, Pittock SJ.

J Neuroimmunol. 2018 Oct 15;323:62-72. doi: 10.1016/j.jneuroim.2018.07.009. Epub 2018 Jul 25.

PMID:
30196836
39.

Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1.

Feyissa AM, Lamb C, Pittock SJ, Gadoth A, McKeon A, Klein CJ, Britton JW.

Epilepsia Open. 2018 Jun 25;3(3):348-356. doi: 10.1002/epi4.12226. eCollection 2018 Sep.

40.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL.

Ann Rheum Dis. 2019 Jan;78(1):150-152. doi: 10.1136/annrheumdis-2018-213777. Epub 2018 Sep 5. No abstract available.

41.

Posttransplant autoimmune encephalitis.

Cohen DA, Lopez-Chiriboga AS, Pittock SJ, Gadoth A, Zekeridou A, Boilson BA, Hogan WJ, Poterucha JJ, Wilton KM, Lin Y, Flanagan EP.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(6):e497. doi: 10.1212/NXI.0000000000000497. eCollection 2018 Nov. No abstract available.

42.

LGI1 and CASPR2 neurological autoimmunity in children.

López-Chiriboga AS, Klein C, Zekeridou A, McKeon A, Dubey D, Flanagan EP, Lennon VA, Tillema JM, Wirrell EC, Patterson MC, Gadoth A, Aaen JG, Brenton JN, Bui JD, Moen A, Otten C, Piquet A, Pittock SJ.

Ann Neurol. 2018 Sep;84(3):473-480. doi: 10.1002/ana.25310.

PMID:
30076629
43.

Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.

Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ.

Am J Ophthalmol. 2018 Nov;195:8-15. doi: 10.1016/j.ajo.2018.07.020. Epub 2018 Jul 26.

44.

Spontaneous posterior spinal artery infarction: An under-recognized cause of acute myelopathy.

Zalewski NL, Rabinstein AA, Wijdicks EFM, Petty GW, Pittock SJ, Mantyh WG, Flanagan EP.

Neurology. 2018 Aug 28;91(9):414-417. doi: 10.1212/WNL.0000000000006084. Epub 2018 Jul 25. No abstract available.

PMID:
30045962
45.

Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis.

Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):488-490. doi: 10.1136/jnnp-2018-318004. Epub 2018 Jul 21. No abstract available.

PMID:
30032117
46.

Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.

López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ.

JAMA Neurol. 2018 Nov 1;75(11):1355-1363. doi: 10.1001/jamaneurol.2018.1814.

47.

Autoimmune septin-5 cerebellar ataxia.

Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, Fryer JP, Devine M, Flores A, Lennon VA, Pittock SJ, McKeon A.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 9;5(5):e474. doi: 10.1212/NXI.0000000000000474. eCollection 2018 Sep. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Dec 12;6(1):e534.

48.

Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year.

Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, Pittock SJ, Basal E, Drubach DA, Lachance DH, Lennon VA, McKeon A.

J Neuroimmunol. 2018 Aug 15;321:157-163. doi: 10.1016/j.jneuroim.2018.04.016. Epub 2018 Apr 27.

PMID:
29793728
49.

Elevated LGI1-IgG CSF index predicts worse neurological outcome.

Gadoth A, Zekeridou A, Klein CJ, Thoreson CJ, Majed M, Dubey D, Flanagan EP, McKeon A, Jenkins SM, Lennon VA, Pittock SJ.

Ann Clin Transl Neurol. 2018 Apr 2;5(5):646-650. doi: 10.1002/acn3.561. eCollection 2018 May.

50.

Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.

Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, McKeon A, Lennon VA, Leavitt JA, Tillema JM, Lucchinetti C, Keegan BM, Kantarci O, Khanna C, Jenkins SM, Spears GM, Sagan J, Pittock SJ.

Ophthalmology. 2018 Oct;125(10):1628-1637. doi: 10.1016/j.ophtha.2018.03.041. Epub 2018 Apr 30.

PMID:
29716788

Supplemental Content

Loading ...
Support Center